Bio-Techne (TECH) Assets Average (2010 - 2026)
Bio-Techne's quarterly Assets Average came in at $2.5 billion in Q1 2026, down 4.54% year-on-year from $2.7 billion in Q1 2025, and little changed quarter-over-quarter from $2.5 billion in Q4 2025.
Bio-Techne has reported Assets Average for 17 years, with the latest figure at $2.5 billion in Q1 2026.
- For the quarter ending Q1 2026, Assets Average fell 4.54% year-over-year to $2.5 billion; the trailing twelve-month figure through Mar 2026 stood at $2.5 billion (down 4.54% YoY), and the FY2025 full-year result was $2.6 billion, down 1.51% from the prior year.
- Assets Average for Q1 2026 stood at $2.5 billion, roughly flat from $2.5 billion in the prior quarter.
- The five-year high for Assets Average was $2.7 billion in Q4 2023, with the low at $2.3 billion in Q2 2022.
- Average Assets Average over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2025.
- Year-over-year, Assets Average gained 16.38% in 2023 and dropped 6.61% in 2025.
- Tracing TECH's Assets Average over 5 years: stood at $2.4 billion in 2022, then grew by 16.38% to $2.7 billion in 2023, then slipped by 1.45% to $2.7 billion in 2024, then dropped by 6.61% to $2.5 billion in 2025, then advanced by 0.48% to $2.5 billion in 2026.
- The last three Assets Average figures came in at $2.5 billion (Q1 2026), $2.5 billion (Q4 2025), and $2.5 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 13.04 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 33.42 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.72 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 331.70 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 40.89 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 26.06 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 26.03 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 40.71 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 5.05 Bn |
| 10 | Bio-Techne | 7.92 Bn | 7.71 Bn | 208.29 Mn | 2.54 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.54 Bn |
| Dec 31, 2025 | 2.52 Bn |
| Sep 30, 2025 | 2.54 Bn |
| Jun 30, 2025 | 2.60 Bn |
| Mar 31, 2025 | 2.66 Bn |
| Dec 31, 2024 | 2.70 Bn |
| Sep 30, 2024 | 2.72 Bn |
| Jun 30, 2024 | 2.71 Bn |
| Mar 31, 2024 | 2.73 Bn |
| Dec 31, 2023 | 2.74 Bn |
| Sep 30, 2023 | 2.70 Bn |
| Jun 30, 2023 | 2.62 Bn |
| Mar 31, 2023 | 2.48 Bn |
| Dec 31, 2022 | 2.36 Bn |
| Sep 30, 2022 | 2.32 Bn |
| Jun 30, 2022 | 2.30 Bn |
| Mar 31, 2022 | 2.30 Bn |
| Dec 31, 2021 | 2.29 Bn |
| Sep 30, 2021 | 2.27 Bn |
| Jun 30, 2021 | 2.17 Bn |
| Mar 31, 2021 | 2.08 Bn |
| Dec 31, 2020 | 2.06 Bn |
| Sep 30, 2020 | 2.04 Bn |
| Jun 30, 2020 | 2.01 Bn |
| Mar 31, 2020 | 2.00 Bn |
| Dec 31, 2019 | 1.96 Bn |
| Sep 30, 2019 | 1.90 Bn |
| Jun 30, 2019 | 1.88 Bn |
| Mar 31, 2019 | 1.86 Bn |
| Dec 31, 2018 | 1.86 Bn |
| Sep 30, 2018 | 1.73 Bn |
| Jun 30, 2018 | 1.61 Bn |
| Mar 31, 2018 | 1.59 Bn |
| Dec 31, 2017 | 1.54 Bn |
| Sep 30, 2017 | 1.54 Bn |
| Jun 30, 2017 | 1.55 Bn |
| Mar 31, 2017 | 1.53 Bn |
| Dec 31, 2016 | 1.52 Bn |
| Sep 30, 2016 | 1.32 Bn |
| Jun 30, 2016 | 1.13 Bn |
| Mar 31, 2016 | 1.13 Bn |
| Dec 31, 2015 | 1.13 Bn |
| Sep 30, 2015 | 1.10 Bn |
| Jun 30, 2015 | 1.08 Bn |
| Mar 31, 2015 | 1.11 Bn |
| Dec 31, 2014 | 1.07 Bn |
| Sep 30, 2014 | 940.38 Mn |
| Jun 30, 2014 | 846.53 Mn |
| Mar 31, 2014 | 816.37 Mn |
| Dec 31, 2013 | 790.73 Mn |
| Sep 30, 2013 | 778.69 Mn |
| Jun 30, 2013 | 769.19 Mn |
| Mar 31, 2013 | 742.43 Mn |
| Dec 31, 2012 | 718.60 Mn |
| Sep 30, 2012 | 715.98 Mn |
| Jun 30, 2012 | 701.68 Mn |
| Mar 31, 2012 | 654.14 Mn |
| Dec 31, 2011 | 626.34 Mn |
| Sep 30, 2011 | 623.05 Mn |
| Jun 30, 2011 | 600.24 Mn |
| Mar 31, 2011 | 569.21 Mn |
| Dec 31, 2010 | 547.62 Mn |
| Sep 30, 2010 | 529.22 Mn |